Lovenox is a prescription drug used to treat or prevent certain types of blood clots. Learn how to lower long-term costs, and more.

Did you ever pay out of pocket for the drug Lovenox? If so, then you might get some cash. Nashville General negotiates $120 million class-action settlement with two drug companies, Momenta and Sandoz.

Thankfully, there are many treatment options available for blood clots during pregnancy. One of the most popular treatments ...

A federal judge held off a decision on whether to bar a generic version of Sanofi-Aventis SA's big-selling drug Lovenox, in a lengthy court hearing that highlighted the stakes for a new generation ...

WASHINGTON—The Food and Drug Administration approved the first generic version of the big-selling blood thinner Lovenox, hitting Sanofi-Aventis SA and bringing a victory to Novartis AG's ...

The FDA has granted Sandoz approval of a generic version of Lovenox (enoxaparin sodium injection, from sanofi aventis).Enoxaparin sodium injection is expected to be made available by Sandoz in ...

We cannot explain why the rate was 8.8% in our study, but rates of close to 10% were recorded with the use of enoxaparin every 12 hours after knee replacement in two recent trials that also ...

Patients were given either Lovenox or a standard therapy. In the Lovenox group, 9.9 percent of patients experienced … Lovenox reduces cardio risks but can cause bleeding | Fierce Biotech ...

Lovenox is one of the leading hospital medications in the US with sales of about $3 billion ($4.3 billion globally). Sanford Bernstein’s Tim Anderson predicted that Sanofi would hang on to a ...

BOSTON (MarketWatch) -- Momenta Pharmaceuticals shares tumbled 21% to $15.10 on Thursday in the wake of a federal appeals court ruling related to its ongoing battle to keep a competing generic ...

We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty.In this randomized, double-blind trial, 2531 ...

Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb and Pfizer, was statistically superior to Sanofi-Aventis' Lovenox (enoxaparin) in reducing the incidence of venous ...